Goldman Sachs’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Goldman Sachs’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-707,039	Closed	-$32.8M	–	6038
2023 Q2	$32.8M	Buy	707,039 +549,422	+349%	+$19M	0.01%	1420
2023 Q1	$4.52M	Sell	157,617 -13,390	-8%	-$397K	﹤0.01%	3162
2022 Q4	$5.34M	Buy	171,007 +128,646	+304%	+$4.2M	﹤0.01%	3109
2022 Q3	$859K	Buy	42,361 +28,211	+199%	+$514K	﹤0.01%	4617
2022 Q2	$220K	Buy	14,150 +1,115	+9%	+$19.2K	﹤0.01%	5601
2022 Q1	$249K	Buy	+13,035	New	+$233K	﹤0.01%	5764
2021 Q4	–	Sell	-39,000	Closed	-$1.28M	–	6789
2021 Q3	$1.28M	Buy	+39,000	New	+$1.33M	﹤0.01%	4563

Goldman Sachs's DICE Position: Q3 2023 in Review

Goldman Sachs sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 707,039 shares — an estimated $32.8M sold.

Goldman Sachs first reported a position in DICE in Q3 2021 and held it in 7 quarters. The position peaked at $32.8M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Goldman Sachs reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Goldman Sachs sold 707,039 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $32.8M.
Goldman Sachs first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Goldman Sachs's DICE Therapeutics, Inc. Common Stock position peaked at $32.8M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.